FDA Reconsiders Curbs on Avandia

The Wall Street Journal (online registration required): Food and Drug Administration documents released Monday suggested the agency was considering reviving a drug that has been highly restricted for nearly three years—the GlaxoSmithKline GSK.LN +0.03% PLC diabetes pill Avandia—and restoring it to full marketing status in the U.S.

Read article

i360Gov Newsletters

The most significant government policy, business, and technology news and analysis delivered to your inbox.

Subscribe Now

Trending